MTOR (Ab-2448) Antibody
Description
Introduction
The MTOR (Ab-2448) Antibody is a highly specific immunological tool designed to detect phosphorylation at Serine 2448 (S2448) of the mammalian target of rapamycin (mTOR), a serine/threonine kinase critical for regulating cellular growth, metabolism, and survival. This phosphorylation site is a hallmark of mTOR activation via the PI3K/Akt signaling pathway, making the antibody a valuable resource for studying mTOR's role in cancer, metabolic disorders, and cellular homeostasis .
Structure and Function of MTOR
mTOR exists in two distinct complexes: mTORC1 and mTORC2. Phosphorylation at S2448 is a key indicator of mTORC1 activity, which integrates signals from nutrients, hormones, and energy status to regulate processes such as protein synthesis, autophagy, and cell proliferation. Aberrant mTOR signaling is frequently observed in tumors, making it a therapeutic target in oncology .
Applications of the MTOR (Ab-2448) Antibody
The antibody is utilized across multiple experimental platforms:
Research Findings
-
Cancer Biology: The antibody has been used to validate mTOR activation in lung cancer tissues, correlating with tumor progression .
-
Cell Signaling: Studies employing the Invitrogen MRRBY monoclonal antibody demonstrate its utility in monitoring mTORC1 activity downstream of PI3K/Akt signaling .
-
Metabolism: Research with the Affinity Biosciences AF3308 antibody highlights mTOR's role in glucose uptake and glycolysis regulation .
Product Comparisons
| Product | Host | Clonality | Applications | Reactivity |
|---|---|---|---|---|
| Invitrogen MRRBY (12-9718-42) | Mouse | Monoclonal | Flow Cytometry | Human, Mouse |
| Rockland 600-401-897 | Rabbit | Polyclonal | WB, ELISA | Human, Rat |
| GeneTex GTX132803 | Rabbit | Polyclonal | WB, IHC, IF | Human, Mouse, Rat, Fish |
| Affinity Biosciences AF3308 | Rabbit | Polyclonal | WB, IHC, IF | Human, Mouse, Rat, Predicted in others |
Product Specs
Target Background
Activated mTORC1 upregulates protein synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis. This includes phosphorylation of EIF4EBP1, releasing its inhibitory effect on the elongation initiation factor 4E (eiF4E). Additionally, mTORC1 phosphorylates and activates RPS6KB1 and RPS6KB2, which further promote protein synthesis by modulating the activity of their downstream targets, including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4.
The mTORC1 signaling cascade also controls the MiT/TFE factors TFEB and TFE3. Under nutrient-rich conditions, mTORC1 mediates the phosphorylation of TFEB and TFE3, promoting their cytosolic retention and inactivation. Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity.
mTORC1 stimulates the pyrimidine biosynthesis pathway through both acute and delayed regulation. It acutely regulates the pathway by RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD. Delayed regulation occurs through transcriptional enhancement of the pentose phosphate pathway, which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis. This function is dependent on the mTORC1 complex.
mTORC1 regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1, an RNA polymerase III repressor. In parallel with protein synthesis, mTORC1 also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1. To maintain energy homeostasis, mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A.
mTORC1 negatively regulates autophagy through phosphorylation of ULK1. Under nutrient sufficiency, mTORC1 phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1. It also prevents autophagy through phosphorylation of the autophagy inhibitor DAP. Additionally, mTORC1 prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions and by mediating phosphorylation of AMBRA1, inhibiting its ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA.
mTORC1 exerts a feedback control on upstream growth factor signaling, including phosphorylation and activation of GRB10, an INSR-dependent signaling suppressor. Among other potential targets, mTORC1 may phosphorylate CLIP1 and regulate microtubules.
As part of the mTORC2 complex, MTOR may regulate other cellular processes, including survival and organization of the cytoskeleton. It plays a critical role in the phosphorylation at 'Ser-473' of AKT1, a pro-survival effector of phosphoinositide 3-kinase, facilitating its activation by PDK1. mTORC2 may regulate the actin cytoskeleton through phosphorylation of PRKCA, PXN, and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B. mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422'.
MTOR regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms. It plays an important regulatory role in the circadian clock function, regulating period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks. MTOR phosphorylates SQSTM1, promoting interaction between SQSTM1 and KEAP1 and subsequent inactivation of the BCR(KEAP1) complex.
- Silencing of TRPC5 and inhibition of autophagy reverses adriamycin drug resistance in breast carcinoma via CaMKKbeta/AMPKalpha/mTOR pathway. PMID: 28600513
- Studies indicate that understanding mTOR network circuitry will provide insight into its deregulation in diabetes, cancer, and cardiovascular disease, but modeling in silico to elucidate how insulin activates mTORC2 remains poorly defined. PMID: 22457328
- L-type amino acid transporter 1 (LAT1) inhibitor, BCH reduces the phosphorylation of mechanistic target of rapamycin kinase (mTOR) in fibroblast-like synoviocytes from patients with rheumatoid arthritis. mTOR inhibitor, temsirolimus, neutralizes the stimulation of interleukin-17 on LAT1. PMID: 29198077
- These results indicate that, under stressful conditions, maintained mTORC1 signaling in cancer cells promotes survival by suppressing endogenous DNA damage, and may control cell fate through the regulation of CHK1. PMID: 28484242
- Results demonstrated that ASCT2 and pmTOR protein levels were significantly higher in epithelial ovarian cancer (EOC) tissues and predicting a poor prognosis. The expression levels of ASCT2 and pmTOR in EOC were positively correlated indicating a synergistic effect on the growth and development of early EOC. PMID: 30272366
- DEPTOR interaction with mTOR represses its kinase activity and rewires the mTOR signaling pathway. [review] PMID: 29897294
- both SphK1 overexpression and S1P addition increased mTOR phosphorylation as shown by ELISA, while S1PR2 inhibition had the inverse effect. These data suggest that CerS6 and SphK1 regulate mTOR signaling in breast cancer cell proliferation. Moreover, mTOR activity can be regulated by the balance between S1P and C16ceramide, which is generated by CerS6. PMID: 30226616
- Study demonstrate that the miR-495 exerts promotive effects on GC chemosensitivity via inactivation of the mTOR signaling pathway by suppressing ERBB2. The study provides reliable evidence supporting the use of miR-495 as a novel potential target in the chemotherapy of GC. PMID: 30147110
- a functional convergence between the mTOR pathway and IFITM3 proteins at endolysosomal membranes. PMID: 30301809
- data on TFEB nucleo-cytoplasmic shuttling suggest an unpredicted role of mTOR in nuclear export. PMID: 30120233
- In this review, we assess the use of mTOR inhibitors to treat age-related pathologies, discuss possible molecular mechanisms of action where evidence is available, and consider strategies to minimize undesirable side effects. PMID: 30096787
- The expression of CXCR4 and mTOR were found to be negatively correlated with remission. Kaplan-Meier analysis indicated a significant decrease in the rate of progression-free survival (PFS) and in that of overall survival (OS) in patients positive for CXCR4 and mTOR expression. PMID: 28952842
- results demonstrated that SSd induces autophagy through the CaMKKbeta-AMPK-mTOR signalling pathway in Autosomal dominant polycystic kidney disease (ADPKD) cells, indicating that SSd might be a potential therapy for ADPKD and that SERCA might be a new target for ADPKD treatment. PMID: 29675630
- findings indicated that shikonin inhibits proliferation and promotes apoptosis in human endometrioid endometrial cancer (EEC) cells by modulating the miR-106b/PTEN/AKT/mTOR signaling pathway, suggesting shikonin could act a potential therapeutic agent in the EEC treatment. PMID: 29449346
- Mammalian target of rapamycin pathway promotes aerobic glycolysis in esophageal squamous cell carcinoma by upregulating pyruvate kinase M2 isoform PMID: 29916308
- The p53 dependence of Plk2 loss and tumor suppressor function in relationship to mTOR signaling may have therapeutic implications. PMID: 29448085
- Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer. PMID: 29862445
- these findings uncover a novel mechanism by which PML loss may contribute to mTOR activation and cancer progression via dysregulation of basal DDIT4 gene expression. PMID: 28332630
- High mTOR expression is associated with periodontitis. PMID: 30218719
- This review intends to provide an outline of the principal biological and molecular functions of mTOR. PMID: 30110936
- High mTOR expression is associated with Pancreatic Ductal Adenocarcinoma Metastasis. PMID: 29386088
- High mTOR expression is associated with prostate cancer. PMID: 29566977
- Studies indicate that dysregulation leads to a number of metabolic pathological conditions, including obesity and type 2 diabetes [Review]. PMID: 30011848
- In ASS1-knockout cells, DEPTOR, an inhibitor of mTORC1 signal, was downregulated and mTORC1 signaling was more activated in response to arginine. PMID: 28358054
- This review addresses the role of mTOR-dependent autophagy dysfunction in a variety of neuropsychiatric disorders, to focus mainly on psychiatric syndromes including schizophrenia and drug addiction. [review] PMID: 30061532
- This article reviews the role of mTOR in cellular processes involved in cancer cachexia and highlights the studies supporting the contribution of mTOR in cancer cachexia. [review] PMID: 30061533
- High mTOR expression is associated with aggressive pathology in urologic cancers. PMID: 29657089
- miR-212 and mTOR signalings may form a positive regulation loop in maintaining cellular homeostasis. PMID: 30021100
- High p-mTOR expression is associated with increased lymphangiogenesis and lymph node metastasis in prostate adenocarcinoma. PMID: 29544697
- RIO kinase 3 (RIOK3) positively regulates the activity of the AKT/mTOR pathway in glioma cells. PMID: 29233656
- Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. PMID: 30224479
- Results show that mTOR expression is regulated by PPP2R2D which influences its protein phosphorylation level contributing to gastric cancer progression. PMID: 29568966
- We performed quantitative mass spectrometry of IAV1918-infected cells to measure host protein dysregulation. Selected proteins were validated by immunoblotting and phosphorylation levels of members of the PI3K/AKT/mTOR pathway were assessed. PMID: 29866590
- Using an mTORspecific signalling pathway phospho array we revealed that NVPBEZ235 significantly decreased phosphorylation of 4EBP1 (Thr70), the downstream target of mTORC1. PMID: 29845289
- The essential role of mTOR in the endocrine therapy resistance in estrogen receptor-positive, HER2-negative breast cancer.[review] PMID: 29086897
- MiR-206 inhibits the development of epithelial ovarian cancer cell by directly targeting c-Met and inhibiting the c-Met/AKT/mTOR signaling pathway. PMID: 29807226
- our findings identified LSD1 as a novel negative regulator of autophagy through the mTOR signaling pathway in ovarian cancer HO8910 cells and indicated that LSD1 may function as a driving factor of ovarian cancer progression via deregulating autophagy. PMID: 29749504
- These results suggested that silibinin induced glioblastoma cell apoptosis concomitant with autophagy which might be due to simultaneous inhibition of mTOR and YAP and silibinin induced autophagy exerted a protective role against cell apoptosis in both A172 and SR cells. PMID: 29780826
- BEX4 positively regulated the expression of OCT4, silencing of which reduced the proliferation of A549 and H1975cells with over-expressed BEX4. PMID: 29660335
- Study demonstrates that high mTOR expression is associated with poor clinical outcome in acute lymphoblastic leukemia. PMID: 29076004
- mTOR drives innate-like antibody responses by linking proximal transmembrane activator and CAML interactor signaling events with distal immunometabolic transcription programs. PMID: 29133782
- piperine reduced the expression of pAkt, MMP9 and pmTOR. Together, these data indicated that piperine may serve as a promising novel therapeutic agent to better overcome prostate cancer metastasis. PMID: 29488612
- Generation of 2-hydroxyglutarate by mutated IDH1/2 leads to the activation of mTOR by inhibiting KDM4A. PMID: 27624942
- High mTOR expression is associated with gastric cancer. PMID: 29328491
- The authors demonstrate that, particularly when autophagy is upregulated, varicella-zoster virus inhibits mTOR-mediated late-stage autophagic flux, likely at the point where autophagosomes and lysosomes fuse or where vesicle contents are degraded. Importantly, inhibition of autophagy yields higher varicella-zoster virus titers. PMID: 30053655
- Identification of a functional mTOR targeted multigene signature robustly discriminates between normal prostate tissues, primary tumors, and hormone refractory metastatic samples but is also predictive of cancer recurrence PMID: 28724614
- 2-ME reduced the production of CTGF and collagen I in SSc fibroblasts induced by hypoxia through PI3K/Akt/mTOR/HIF-1alpha signalling and inhibited the proliferation of fibroblasts. These findings suggested that 2-ME could be employed as a promising antifibrotic therapy for SSc PMID: 29905853
- miR33a5p inhibited the proliferation of lung adenocarcinoma cells, enhanced the antitumor effect of celastrol, and improved sensitivity to celastrol by targeting mTOR in lung adenocarcinoma in vitro and in vivo PMID: 29484434
- miR-181 may be a novel and important regulator of cisplatin-resistant non-small cell lung cancer by serving a role in the regulation of apoptosis, as an established rate-limiting miRNA target. PMID: 29484437
- Evaluation of the potential mechanism demonstrated that TRIM28 promoted cervical cancer cell growth by activating the mammalian target of rapamycin (mTOR) signaling pathway. In support of this finding, TRIM28-induced cell proliferation was abolished by treatment with everolimus, a specific mTOR inhibitor PMID: 29393469
Q&A
What is the mTOR (Ser2448) antibody and what does it specifically detect?
The phospho-mTOR (Ser2448) antibody specifically recognizes the mammalian target of rapamycin (mTOR) protein only when phosphorylated at the serine 2448 position. mTOR is a 289 kDa serine/threonine protein kinase that functions as an ATP and amino acid sensor, balancing nutrient availability with cellular processes including growth, proliferation, motility, survival, protein synthesis, and transcription. This antibody is crucial for studying the activation state of mTOR, as phosphorylation at Ser2448 occurs via the PI3 kinase/Akt signaling pathway and indicates active mTOR signaling .
What species reactivity does the phospho-mTOR (Ser2448) antibody exhibit?
The phospho-mTOR (Ser2448) antibody demonstrates reactivity across multiple species, including human, mouse, and rat samples. This cross-species reactivity is particularly valuable for comparative studies. Some antibodies, such as the one available from Cell Signaling Technology, share 100% sequence homology with monkey (Mk) samples, suggesting potential reactivity, though this may require validation by the researcher . The broad species reactivity makes this antibody versatile for researchers working with different model organisms.
What are the available formats and sources of phospho-mTOR (Ser2448) antibodies?
Phospho-mTOR (Ser2448) antibodies are available in both polyclonal and monoclonal formats from various suppliers. Polyclonal antibodies, such as those from GeneTex (GTX132803), are raised in rabbits and recognize multiple epitopes on the phosphorylated protein . Monoclonal antibodies, like the MRRBY clone from Invitrogen conjugated with eFluor, recognize a single epitope and may offer higher specificity for certain applications . The choice between these formats depends on the experimental requirements, with monoclonal antibodies generally providing higher specificity while polyclonal antibodies may offer greater sensitivity.
What applications are supported by phospho-mTOR (Ser2448) antibodies?
Phospho-mTOR (Ser2448) antibodies support multiple experimental applications, with specific validated protocols varying by manufacturer. Common applications include:
-
Western Blotting (WB): Typically used at 1:1000 dilution for standard Western blotting and 1:10-1:50 for Simple Western systems .
-
Immunocytochemistry/Immunofluorescence (ICC/IF): Successfully used to detect phospho-mTOR in fixed cells, typically at 1:500 dilution .
-
Immunohistochemistry on paraffin-embedded tissues (IHC-P): Effective for tissue sections with appropriate antigen retrieval methods .
-
Flow Cytometry: Monoclonal antibodies like the MRRBY clone are pre-titrated for intracellular staining followed by flow cytometric analysis of cells, using approximately 0.5 μg per test of 10^5 to 10^8 cells .
The choice of application should be guided by the specific research question and available facilities.
What is the recommended protocol for Western blotting using phospho-mTOR (Ser2448) antibody?
For optimal Western blotting results with phospho-mTOR (Ser2448) antibody, follow this detailed protocol:
-
Sample Preparation: Extract total protein from cells or tissues using a lysis buffer containing phosphatase inhibitors to preserve phosphorylation status.
-
Gel Selection: Use a 5% SDS-PAGE gel due to the large size of mTOR (289 kDa) .
-
Protein Loading: Load approximately 30 μg of protein per well for cell extracts .
-
Antibody Dilution: Use the primary phospho-mTOR (Ser2448) antibody at 1:1000 dilution .
-
Secondary Antibody: Apply HRP-conjugated anti-rabbit IgG antibody for detection .
-
Controls: Include both treated (phosphorylation-inducing conditions) and untreated samples to demonstrate specificity .
This methodological approach ensures reliable detection of phosphorylated mTOR while minimizing background signal.
What protocol should be followed for immunohistochemistry using phospho-mTOR (Ser2448) antibody?
For successful immunohistochemical detection of phospho-mTOR (Ser2448) in tissue sections, implement this protocol:
-
Sample Fixation: Use paraffin-embedded tissue sections.
-
Antigen Retrieval: Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) for 15 minutes .
-
Blocking: Block non-specific binding sites with an appropriate blocking solution.
-
Primary Antibody: Apply phospho-mTOR (Ser2448) antibody at 1:500 dilution .
-
Detection System: Use an appropriate detection system compatible with the primary antibody host species.
-
Peptide Competition: For specificity validation, perform parallel staining with control peptide and antigen-specific peptide .
-
Counterstaining: Apply nuclear counterstain as needed for visualization of tissue architecture.
This protocol has been validated for detecting cytoplasmic phospho-mTOR in human lung cancer samples .
How can I verify the specificity of phospho-mTOR (Ser2448) antibody signal?
Verifying phospho-mTOR (Ser2448) antibody specificity requires multiple control experiments:
-
Peptide Competition Assay: Compare staining between samples treated with control peptide versus antigen-specific peptide. The signal should be abolished in the presence of the specific phospho-peptide .
-
Phosphatase Treatment: Treat one set of samples with lambda phosphatase to remove phosphorylation; the signal should disappear in these samples.
-
Stimulation/Inhibition Controls: Include samples from cells treated with mTOR pathway activators (e.g., insulin) and inhibitors (e.g., rapamycin) to demonstrate signal modulation.
-
Knockout/Knockdown Validation: If available, use mTOR knockout or knockdown samples as negative controls.
-
Molecular Weight Verification: Confirm that the detected band appears at the expected molecular weight (289 kDa) .
These complementary approaches provide robust validation of antibody specificity and prevent misinterpretation of non-specific signals.
What are common issues in phospho-mTOR (Ser2448) Western blot detection and how can they be resolved?
When encountering problems with phospho-mTOR (Ser2448) detection in Western blots, consider these solutions:
| Problem | Potential Cause | Solution |
|---|---|---|
| No signal | Rapid dephosphorylation during sample handling | Add phosphatase inhibitors to all buffers; keep samples cold |
| Weak signal | Insufficient protein loading | Increase protein concentration; mTOR is a large protein (289 kDa) and may require higher loading |
| Multiple bands | Non-specific binding or degradation products | Optimize blocking conditions; ensure fresh samples with protease inhibitors |
| High background | Insufficient blocking or washing | Increase blocking time; add more wash steps with higher stringency |
| Inconsistent results | Variations in cell signaling status | Standardize cell culture conditions and harvesting protocols |
Additionally, for this large protein (289 kDa), extended transfer times may be necessary, and using a gradient gel can improve resolution .
How should I optimize phospho-mTOR (Ser2448) antibody for flow cytometry applications?
For optimal flow cytometry results with phospho-mTOR (Ser2448) antibody:
-
Cell Preparation: Properly fix and permeabilize cells using formaldehyde followed by methanol or a commercial permeabilization buffer.
-
Antibody Titration: Though recommended at 0.5 μg per test, perform a titration experiment (0.1-1.0 μg) to determine optimal signal-to-noise ratio for your specific cell type .
-
Protocol Selection: Choose between one-step or two-step protocols based on your experimental needs. The two-step protocol allows greater flexibility for detecting both surface and intracellular proteins .
-
Controls: Include isotype controls, unstimulated cells, and positive controls (cells with known mTOR activation).
-
Compensation: When using multiple fluorophores, proper compensation is critical, especially with the eFluor conjugated antibodies .
-
Cell Concentration: Optimize between 10^5 to 10^8 cells per test, with higher concentrations potentially requiring adjusted antibody amounts .
This methodological approach ensures reliable quantification of phospho-mTOR across different cell populations.
How can phospho-mTOR (Ser2448) antibody be utilized in multiplex assays?
Implementing phospho-mTOR (Ser2448) antibody in multiplex assays allows simultaneous detection of multiple signaling pathway components:
-
Sandwich Immunoassay Format: Use a capture antibody for total mTOR coated on electrodes/spots, with detection antibody specifically recognizing the phospho-Ser2448 site .
-
Electrochemiluminescent Detection: Utilize conjugated detection antibodies (e.g., SULFO-TAG label) that complete the sandwich when analyte binds to the capture antibody .
-
Multi-Array Plates: Implement 96-well formats with strategic combinations of antibodies targeting various components of the PI3K/Akt/mTOR pathway.
-
Sample Preparation: Prepare complete lysis buffer immediately before sample dilution to preserve phosphorylation status .
-
Protocol Optimization: Follow manufacturer-recommended blocking, washing, and incubation times (typically 1-3 hours with vigorous shaking at 300-1000 rpm) .
This advanced approach enables comprehensive pathway analysis while conserving valuable sample material.
What are the considerations for using phospho-mTOR (Ser2448) antibody in cancer research?
When applying phospho-mTOR (Ser2448) antibody in cancer research contexts:
-
Tissue-Specific Optimization: Different cancer types show variable expression and phosphorylation levels of mTOR, requiring protocol adjustments. For example, lung cancer samples have been successfully analyzed with 1:500 antibody dilution and citrate buffer antigen retrieval .
-
Clinical Correlation: Correlate phospho-mTOR (Ser2448) levels with patient outcomes, treatment responses, and other clinical parameters.
-
Therapy Response Monitoring: Use the antibody to assess changes in mTOR activation following treatment with mTOR inhibitors or other targeted therapies.
-
Pathway Crosstalk Analysis: Combine with antibodies against other phospho-proteins (e.g., phospho-Akt, phospho-S6K) to map signaling networks.
-
Tumor Heterogeneity Assessment: Analyze spatial distribution of phospho-mTOR within tumor sections to identify regions of differential signaling activity.
This approach has been validated in published cancer research, including studies in aging-related cancer development (PMID: 31831718) .
How can phospho-mTOR (Ser2448) antibody be utilized in studying metabolic disorders?
For metabolic disorder research applications:
-
Tissue Selection: Focus on metabolically active tissues (liver, muscle, adipose tissue) where mTOR regulates glucose metabolism, lipid synthesis, and energy homeostasis.
-
Nutritional Status Correlation: Compare phospho-mTOR (Ser2448) levels across fasting, feeding, and various dietary interventions.
-
Insulin Signaling Integration: Combine with analysis of insulin receptor substrate (IRS) proteins and glucose transporters to map pathway interactions.
-
Animal Models: Validate findings across different metabolic disease models (obesity, diabetes, NAFLD) where mTOR signaling is dysregulated.
-
Specialized Protocols: For adipose tissue, modify extraction protocols to address high lipid content that can interfere with protein detection.
This methodological framework leverages mTOR's role as a nutrient sensor that increases production of enzymes necessary for glycolysis and controls the uptake of glucose and other nutrients when sufficiently available .
